Contamination of samples with DNA is still a major problem in microbiology laboratories, despite the wide acceptance of PCR and other amplification techniques for the detection of frequently low amounts of target DNA. This review focuses on the implications of contamination in the diagnosis and research of infectious diseases, possible sources of contaminants, strategies for prevention and destruction, and quality control. Contamination of samples in diagnostic PCR can have far-reaching consequences for patients, as illustrated by several examples in this review. Furthermore, it appears that the (sometimes very unexpected) sources of contaminants are diverse (including water, reagents, disposables, sample carry over, and amplicon), and contaminants can also be introduced by unrelated activities in neighboring laboratories. Therefore, lack of communication between researchers using the same laboratory space can be considered a risk factor. Only a very limited number of multicenter quality control studies have been published so far, but these showed false-positive rates of 9-57%. The overall conclusion is that although nucleic acid amplification assays are basically useful both in research and in the clinic, their accuracy depends on awareness of risk factors and the proper use of procedures for the prevention of nucleic acid contamination. The discussion of prevention and destruction strategies included in this review may serve as a guide to help improve laboratory practices and reduce the number of false-positive amplification results.
Five azole-susceptible Candida glabrata isolates obtained before 1975 became resistant to fluconazole, itraconazole, and voriconazole within 4 days of in vitro fluconazole exposure. This cross-resistance was stable for at least 4 months after removal of fluconazole and was associated with increased CgCDR1 and CgCDR2 expression.Candida glabrata has become one of the most common causes of Candida bloodstream infections (BSI) worldwide, now accounting for 7.5 to 18.3% of cases in different countries (20). The emergence of C. glabrata is of concern because of recent reports that up to 18% of incident bloodstream isolates are resistant to fluconazole (6,8,20,21). Moreover, resistance to azole antifungal agents, including fluconazole and itraconazole, can emerge rapidly when patients with C. glabrata infection are treated with these drugs (10, 25). Resistance can also emerge when patients, such as hematopoietic stem cell transplant recipients, are given prolonged periods of azole prophylaxis (2). In these cases, both the acquisition of new strains and increased resistance in existing strains have been described (2,10,15). Multiple mechanisms of resistance have been reported, including increased expression of the ABC transporter genes CgCDR1 and CgCDR2 (PDH1), which result in decreased accumulation of intracellular fluconazole (2,11,17,23), and increased expression of the CgERG11 gene encoding the fluconazole target, 14␣-lanosterol demethylase (15,22). Recent studies have described up-regulation of these genes in C. glabrata isolates upon fluconazole exposure (2, 9, 15, 22), including some for which the previous fluconazole exposure history was unknown.We therefore sought to determine whether the rapid acquisition of fluconazole resistance by C. glabrata is an innate characteristic of this organism or whether multiple exposures to azoles over time are required. To ensure that the isolates tested had not been previously exposed to azole antifungal agents, we studied susceptible isolates of C. glabrata obtained between 1917 and 1975, a time period before the first introduction of oral or parenteral formulations of azole drugs. These C. glabrata isolates were then examined for their capacity to become resistant to azoles after in vitro exposure to fluconazole and for the length of time required for isolates to become resistant. In addition, we studied the molecular mechanisms associated with the acquired resistance and the stability over time of such resistance after the removal of fluconazole.Isolates. Three clinical C. glabrata isolates, CBS 138, CBS 860, and CBS 4692, which were isolated in 1917, 1935, and 1960, respectively, were obtained from the Centraalbureau voor Schimmelcultures (CBS), Utrecht, The Netherlands. Two other clinical C. glabrata isolates, 73/124 and 75/015, isolated in 1973 and 1975, were obtained from the University of Aberdeen, Aberdeen, United Kingdom. Species identification was confirmed by using species-specific Candida DNA probes in a PCR-enzyme immunoassay as described previously (7).Antifunga...
The purpose of this study was to develop a method for the depletion of macrophages from the peritoneal cavity and the omentum of the rat. Rats received two intraperitoneal injections (at days 0 and 3) with liposome-encapsulated clodronate (dichloromethylene bisphosphonate: Cl2MBP-liposomes). This treatment resulted in complete elimination of mature tissue macrophages (ED2-positive macrophages) from the peritoneal cavity and the omentum within 2 days. The elimination included the strongly ED2-positive spindle-shaped cells of the omental membrane. Repopulation of the omental ED2-positive macrophages was not seen within the next 23 days. Whereas ED2-positive macrophages were completely depleted, few ED1-positive cells remained and repopulation of ED1-positive cells was faster. The treatment further depleted macrophages from the spleen, especially from the red pulp, parathymic lymph nodes and liver. Freund's incomplete adjuvant administered one day after the last injection of Cl2MBP-liposomes considerably accelerated repopulation in the omentum. The protocol described might be used to investigate the contribution of mature tissue macrophages to the induction of immune responses, drug metabolism and the elimination of intestinal tumours.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.